Genelux (GNLX) and Its Competitors Head to Head Comparison

Genelux (NASDAQ:GNLX) is one of 970 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Genelux to similar companies based on the strength of its dividends, valuation, earnings, risk, institutional ownership, analyst recommendations and profitability.

Institutional and Insider Ownership

37.3% of Genelux shares are held by institutional investors. Comparatively, 44.4% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 11.7% of Genelux shares are held by company insiders. Comparatively, 13.9% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Genelux and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	0	0	4	0	3.00
Genelux Competitors	6451	18725	44081	923	2.56

Genelux currently has a consensus price target of $34.00, suggesting a potential upside of 1,197.71%. As a group, “Pharmaceutical preparations” companies have a potential upside of 75.95%. Given Genelux’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Genelux is more favorable than its peers.

Profitability

This table compares Genelux and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-125.58%	-86.03%
Genelux Competitors	-2,095.05%	-292.90%	-33.81%

Valuation and Earnings

This table compares Genelux and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Genelux	$170,000.00	-$28.30 million	-2.70
Genelux Competitors	$2.07 billion	$152.26 million	-2.93

Genelux’s peers have higher revenue and earnings than Genelux. Genelux is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Genelux has a beta of -1.18, meaning that its stock price is 218% less volatile than the S&P 500. Comparatively, Genelux’s peers have a beta of 1.13, meaning that their average stock price is 13% more volatile than the S&P 500.

Summary

Genelux peers beat Genelux on 7 of the 13 factors compared.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.